Beta-adrenergic blockers and CHF: More rest for the weary
British Journal of Cardiology
Current status of beta-adrenergic blockers and treatment of CHF: After 20 years of investigation with beta-adrenergic blockers in CHF, it has been shown that beta-adrenergic blockers are well tolerated and safe in most patients with Class III and IV CHF. Drug treatment with a variety of beta-adrenergic receptor inhibitors improves symptoms and haemodynamics (ejection fraction, cardiac output, pulmonary capillary wedge pressure and oxygen utilisation) in most patients. What remains unknown is whether beta-adrenergic blockers improve survival in ischaemic and/or nonischaemic cardiomyopathies. Finally, more data is needed to determine if there is a preferred beta-blocking agent, which patients are best suited to treatment, and when to use beta-blockers in CHF?
Katz, R. (1995). Beta-adrenergic blockers and CHF: More rest for the weary. British Journal of Cardiology, 2 (9). Retrieved from https://hsrc.himmelfarb.gwu.edu/smhs_medicine_facpubs/4214